Results Healthcare advises Sovereign Capital Partners on the acquisition of Xendo by ProPharma Group

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: CROs & CMOs
  • Engagement Type: Sell Side
Jul 2018
a Sovereign Capital Partners investment
has been acquired by
a Linden Capital Partners LLC investment

Results Healthcare are delighted to have been the exclusive financial advisor to Sovereign Capital Partners on the divestment of Xendo B.V. to ProPharma Group (a Linden Capital Partners LLC investment).

Xendo, headquartered in The Netherlands with offices in Germany and Sweden, is a leading provider of regulatory affairs, compliance, validation and pharmacovigilance consulting and outsourced services. The company helps biotech, pharmaceutical and medical device companies through all stages of the life cycle of their products. The firm has over 25 years’ experience of helping companies navigate the complex regulatory compliance landscape. Xendo brings with them 200+ experienced professionals offering their expertise on strategic advice and project management.

Sovereign completed a management buy-out of Xendo in 2016 and went on to successfully develop the business through a strategy of organic and acquisitive growth.

ProPharma Group is an industry leader providing pharmacovigilance, medical information, validation, compliance and technical services to the pharmaceutical, biotechnology, medical device and related industries. The firm is headquartered in Overland Park, Kansas and have offices across the US and around the world.

The deal brings together two leading players in the pharmaceutical specialist consulting sector, adding significant depth and breadth to the service offering of ProPharma and increasing their global footprint in key international markets.

Results Healthcare have given us hands-on support and clear guidance every step of the way. They have worked diligently throughout the process and have been committed to achieving a successful outcome.

Jose Rodriguez, Director

Sovereign Capital Partners

Sector Related Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has been acquired by
a Behrman Capital-backed company